Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

bioAffinity Technologies (BIAF) EBIAT: 2022-2025

Historic EBIAT for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -$5.1 million.

  • bioAffinity Technologies' EBIAT fell 152.45% to -$5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.7 million, marking a year-over-year decrease of 74.51%. This contributed to the annual value of -$9.0 million for FY2024, which is 13.89% down from last year.
  • Latest data reveals that bioAffinity Technologies reported EBIAT of -$5.1 million as of Q3 2025, which was down 24.39% from -$4.1 million recorded in Q2 2025.
  • bioAffinity Technologies' 5-year EBIAT high stood at -$88,052 for Q2 2022, and its period low was -$5.1 million during Q3 2025.
  • Over the past 3 years, bioAffinity Technologies' median EBIAT value was -$2.3 million (recorded in 2023), while the average stood at -$2.6 million.
  • Data for bioAffinity Technologies' EBIAT shows a peak YoY increase of 53.43% (in 2023) and a maximum YoY decrease of 1,876.30% (in 2023) over the last 5 years.
  • bioAffinity Technologies' EBIAT (Quarterly) stood at -$1.7 million in 2022, then plummeted by 41.72% to -$2.4 million in 2023, then declined by 25.02% to -$3.0 million in 2024, then tumbled by 152.45% to -$5.1 million in 2025.
  • Its last three reported values are -$5.1 million in Q3 2025, -$4.1 million for Q2 2025, and -$2.7 million during Q1 2025.